Premium
Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis
Author(s) -
Hernandez M. R.,
Tonda R.,
Arderiu G.,
Pino M.,
Serradell M.,
Escolar G.
Publication year - 2005
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2005.01496.x
Subject(s) - antithrombotic , platelet , thrombus , nitric oxide , ex vivo , medicine , in vivo , vasodilation , pharmacology , chemistry , in vitro , biochemistry , biology , microbiology and biotechnology
Background The ability of nitrous compounds to donate nitric oxide (NO), an agent with vasodilating and inhibitory effects on platelet function, has been considered a useful pharmacologic strategy for cardiovascular complications. The purpose of this study was to investigate the effects of a new NO donor, LA419, on platelet interaction in an ex vivo model with human blood circulating through collagen‐rich surfaces. Materials and methods Platelet adhesive and cohesive function were analyzed by morphometric procedures after perfusion techniques. Treated blood was exposed to thrombogenic surfaces and platelet interactions were morphometrically evaluated. Results All the concentrations studied of LA419 (10 µM, 20 µM and 100 µM) reduced overall platelet interaction with a collagen surface (27·19 ± 4·72; 25·52 ± 3·52; and 23·44 ± 3·01, P < 0·05, respectively, vs. 32·31 ± 1·61% in the control). The antithrombotic effect was confirmed by results in cross‐sectional studies performed in arterial vessels exposed to circulating blood. Values of thrombus and covered surface at 20 µM LA419 were, respectively, 13·67 ± 4·97% and 19·01 ± 5·89%; respect to controls 34·80 ± 5·29% and 37·93 ± 5·34% ( P < 0·05). Moreover, LA419 reduced significantly thrombus area (88·45 ± 21·97 µm 2 ; P < 0·05) with respect to controls (168·45 ± 21·97 µm 2 ) and thrombus height, from an average of 10·27 ± 1·05 µm in nontreated blood to 7·16 ± 0·6 µm in treated samples ( P < 0·05). Conclusion From the present data we can conclude that LA419 possesses a strong antiplatelet action, as demonstrated by its ability to significantly inhibit the interaction of platelet with highly thrombogenic collagen surfaces.